10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
Biomarin Pharmaceutical Inc (BMRN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 9,753,293 | $685,558,965 | +39% | 2.49% |
| 2. | Elliott Management Paul Singer | 3,500,338 | $246,038,758 | 1.27% | |
| 3. | VenBio Select Advisor Kurt Von Emster | 2,038,015 | $143,252,074 | -56% | 2.08% |
| 4. | Citadel Investment Group Ken Griffin | 1,204,397 | $84,657,065 | +116% | 0.01% |
| 5. | Palo Alto Investors William Leland Edwards | 1,090,056 | $76,620,036 | -4% | 9.95% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.75 | 3,625 | Director | 10,905 | 2022-10-31 | Filing | |
| $78.84 | 900 | Director | 30,740 | 2020-08-31 | Filing | |
| $78.22 | 11,900 | Director | 29,840 | 2020-08-31 | Filing | |
| $21.76 | 161 | Officer | 100,574 | 2012-10-31 | Filing | |
| $21.76 | 548 | Officer | 15,294 | 2012-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $66.37 | 5,278 | Officer | 68,909 | 2024-11-12 | Filing | |
| $90.00 | 714 | Officer | 14,449 | 2024-08-13 | Filing | |
| $75.19 | 5,000 | Officer | 72,159 | 2024-05-30 | Filing | |
| $75.29 | 2,779 | Officer | 56,157 | 2024-05-28 | Filing | |
| $74.46 | 38,071 | Officer | 58,936 | 2024-05-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,414,374 | $1,775,513,941 | 1.4% | |
| 2. | 18,050,062 | $1,740,386,979 | 0.03% | |
| 3. | 14,681,644 | $1,415,604,123 | 0.03% | |
| 4. | 13,994,063 | $1,349,307,554 | 0.85% | |
| 5. | 10,774,641 | $1,038,906,821 | 0.25% |
News See All
10 Best Genomics Stocks To Buy Right Now
Genomics is the study of genes and how they function.
Here’s Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN)
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The U.S.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Bailey and I will be your conference operator today.
10 Best Falling Stocks To Buy According to Hedge Funds
Analysts at Goldman Sachs on October 21st released a note forecasting that the S&P 500 average annual return of 13% for the past 10 years might come down to just 3% for the next decade.
16 Best Mid Cap Growth Stocks To Buy Now
Recent discussions among financial strategists emphasize the current stock market dynamics, particularly regarding the upcoming US elections.
Top 10 Stock Picks of Elliott Management
It was arguably one of the best years for hedge funds, going by the $67 billion returned to shareholders in 2023 as the overall equity markets shrugged off high interest rates to finish on a high.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2024 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2024 Earnings Call Transcript August 5, 2024BioMarin Pharmaceutical Inc. misses on earnings expectations.
Here’s Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN)
Parnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback?
Scout Investments, Inc, an affiliate of Carillon Tower Advisers, released the “Carillon Scout Mid Cap Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Billionaire Hedge Funds
